Compare TG Therapeutics Inc (TGTX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Xylem, Inc. — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Xylem, Inc. trades at $107.97 (market cap $25.41B). The key difference: Xylem, Inc. is far larger — about 3× TG Therapeutics Inc's market cap, and Xylem, Inc. pays a 1.58% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | XYL | |
|---|---|---|
Market Cap | $8.53B | $25.41B |
Sector | Health | Industrials |
52-Week High | $59.06 | $152.95 |
52-Week Low | $26.94 | $105.69 |
Enterprise Value | $8.74B | $27.18B |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
XYL trades at $108.81, up 2.95% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 10.59% net margin. Recent news highlights strategic acquisitions, a new CFO appointment, and a dividend declaration, supporting growth in water technology sectors. The stock shows resilience with revenue growth from $5.5B in 2022 to $9.04B in 2025, though it faces near-term resistance.
Outlook is cautiously optimistic with a consensus price target of $152.29 implying 40% upside, driven by margin expansion and AI-driven demand. Risks include execution of acquisitions and market volatility, but analyst sentiment leans buy/hold with low sell ratings. The stock presents a value opportunity for long-term investors focused on sustainable water solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
